Document:

Amendment No. 2 to Overadvance Letter

 Exhibit 10.1 
 AMENDMENT NO. 2 
 to OVERADVANCE SIDE-LETTER 
 This AMENDMENT NO. 2 to OVERADVANCE SIDE-LETTER (this “Amendment”), dated as of January 31, 2008, is entered into by and among
Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Parent”), Analytica International, Inc., a Florida corporation (“Analytica”), Teamm Pharmaceuticals, Inc., a Florida corporation
(“Teamm” and, collectively with the Parent and Analytica, the “Companies” and, each a “Company”) and Laurus Master Fund, Ltd., a Cayman Islands company (the “Purchaser”), for the
purpose of amending the terms of the Overadvance Side Letter dated as of August 29, 2007 by and among the Companies and the Purchaser (as amended by that certain Amendment No. 1 to Overadvance Side-Letter dated as of October 21, 2007
by and among the Companies and the Purchaser and as may be further amended, modified or supplemented from time to time, the “Overadvance Side-Letter”) issued in connection with the Amended and Restated Security Agreement, dated as
of April 29, 2005, and amended and restated as of February 13, 2006 by and among the Companies and the Purchaser (as amended and restated, further amended, modified or supplemented from time to time, the “Security
Agreement” and, collectively with the Overadvance Side-Letter and the other Ancillary Agreements referred to in the Security Agreement, the “Loan Documents”). Capitalized terms used herein without definition shall have the
meanings ascribed to such terms in the Security Agreement. 
 WHEREAS, the Companies have requested that the maturity and termination date of
the Overadvances set forth in the Overadvance Side Letter be extended and the Purchaser has agreed to extend the Period (as defined in the Overadvance Side Letter), on the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows: 
 1. The first sentence in the fourth paragraph of the Overadvance Side Letter is hereby
amended by deleting the date “March 31, 2008” appearing therein and inserting the date “April 29, 2008” in lieu thereof. 
 2. Each Company hereby acknowledges and affirms that the amount of the Overadvances outstanding as of the end of business on the date hereof is $2,874,860. 
 3. The amendment set forth above shall be effective as of the date first above written (the “Amendment Effective Date”) on the date when each of the Companies and the Purchaser shall have executed and
each of the Companies shall have delivered to the Purchaser its respective counterpart to this Amendment. 
 4. Except as specifically set
forth in this Amendment, there are no other amendments, modifications or waivers to the Loan Documents and all of the other forms, terms and provisions of the Loan Documents remain in full force and effect. 

 5. Except as set forth in Schedule I hereto, each Company hereby represents and warrants to the Purchaser
that (i) no Event of Default exists on the date hereof, after giving effect to this Amendment, (ii) on the date hereof, all representations, warranties and covenants made by such Company in connection with the Loan Documents are true,
correct and complete and (iii) on the date hereof, all the Company’s and its Subsidiaries’ covenant requirements have been met. 
 6. From and after the Amendment Effective Date, all references in the Loan Documents and in the other Ancillary Agreements to the Overadvance Side Letter shall be deemed to be references to the Overadvance Side Letter, as the case may be,
as modified hereby. 
 7. The Parent understands that the Parent has an affirmative obligation to make prompt public disclosure of material
agreements and material amendments to such agreements. It is the Parent’s determination that neither this Amendment nor the terms and provisions of this Amendment, (collectively, the “Information”) are material. The Company has
had an opportunity to consult with counsel concerning this determination. The Company hereby agrees that the Purchaser shall not be in violation of any duty to the Company or its shareholders, nor shall the Purchaser be deemed to be misappropriating
any information of the Company, if the Purchaser sells shares of common stock of the Company, or otherwise engages in transactions with respect to securities of the Company, while in possession of the Information. 
 8. This Amendment shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the benefit of and be
enforceable by each of the parties hereto and their respective successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may be
executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. 
 [The
remainder of this page is intentionally left blank] 
  

 2 

 IN WITNESS WHEREOF, each of the Company and
the Purchaser has caused this Amendment to the Overadvance Side Letter to be signed in its name effective as of the 31st day of January 2008. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty

	 Name:
	 	James A. McNulty, CPA
	 Title:
	 	Secretary/Treasurer
	
	ANALYTICA INTERNATIONAL, INC.
		
	By:	 	 /s/ James A. McNulty

	 Name:
	 	James A. McNulty, CPA
	 Title:
	 	Secretary
	
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty

	 Name:
	 	James A. McNulty, CPA
	 Title:
	 	Secretary
	
	LAURUS MASTER FUND, LTD.
	By:	 	Laurus Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Patrick Regan

	 Name:
	 	Patrick Regan
	 Title:
	 	Authorized Signatory

 SCHEDULE ILetter Amendment to Accentia Warrants

 Exhibit 10.2 
 as of January 31, 2008 
 Accentia Biopharmaceuticals, Inc. 
 324 South Hyde Park Ave., Suite 350 
 Tampa, Florida 330606 
 Attention: Chief Financial Officer 
 Re: Amendment to Warrants 
 Ladies and Gentlemen: 
 Reference is made to (a) the
Securities Purchase Agreement dated as of April 29, 2005 (as amended, restated, modified and/or supplemented from time to time, the “Securities Purchase Agreement”) by and between Accentia Biopharmaceuticals, Inc., a Florida
corporation (the “Company”) and Laurus Master Fund, Ltd. (“Laurus”); (b) the Amended and Restated Common Stock Purchase Warrant dated August 16, 2005 issued by the Company in favor of Laurus for up to
1,000,000 shares of common stock of the Company (as amended, restated, modified and/or supplemented from time to time, the “2005 Warrant”) and (c) the Common Stock Purchase Warrant dated October 31, 2007 issued by the Company
in favor of Laurus for up to 4,024,398 shares of common stock of the Company (the “2007 Warrant” and, together with the 2005 Warrant, the “Warrants”). Capitalized terms used herein that are not defined shall have
the meanings given to them in the Securities Purchase Agreement. 
 In order to induce Laurus to continue to extend to the Company the
financial accommodations contemplated by the Securities Purchase Agreement, the Company has agreed to amend the Warrants on the terms and conditions set forth below. 
 In consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree that: 
 (i) clause (d) of the 2005 Warrant is hereby amended and restated in its entirety to read as follows: 
 “The “Exercise Price” applicable under this Warrant shall be a price of $2.67 for any shares acquired hereunder.” 
 (ii) the first sentence of Section 1.5 of the 2007 Warrant is hereby amended and restated in its entirety to read as follows: 
 “Notwithstanding anything contained herein to the contrary, at any time prior to March 31, 2008 (the “Warrant Repurchase Date”), the
Company may, at its sole discretion, provide the Holder with written notice (the “Notice of Repurchase”) of its intent to repurchase the Warrant for an aggregate purchase price of Four Million Dollars ($4,000,000) (the “Warrant
Repurchase Price”) or any portion of the Warrant exercisable for no less than fifty percent (50%) of the shares of Common Stock receivable upon exercise of the Warrant for the proportionate Warrant Purchase Price.” 

 This letter agreement shall become effective upon receipt by Laurus of a copy of this letter agreement
executed by the Company. 
 Except as specifically amended herein, the Securities Purchase Agreement, Warrants and the other Related
Agreements (as defined in the Securities Purchase Agreement) shall remain in full force and effect, and are hereby ratified and confirmed. The execution, delivery and effectiveness of this letter agreement shall not operate as a waiver of any right,
power or remedy of Laurus, nor constitute a waiver of any provision of the Securities Purchase Agreement, the Warrants and the other Related Agreements. This letter agreement shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and assigns and shall be governed by and construed in accordance with the laws of the State of New York. 
 [Remainder of Page Intentionally Left Blank] 
  

 2 

 This letter agreement may be executed by the parties hereto in one or more counterparts, each of which
shall be deemed an original and all of which when taken together shall constitute one and the same agreement. Any signature delivered by a party by facsimile transmission shall be deemed to be an original signature hereto. 
  

			
	Very truly yours,
	
	LAURUS MASTER FUND, LTD.
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan
	Title:	 	Authorized Signatory

  

			
	CONSENTED AND AGREED TO:
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty

	Name:	 	James A. McNulty, CPA
	Title:	 	Secretary/Treasurer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]